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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 2-2.5 hours of work and is not intended to be a comprehensive 
summary of evidence. 
Sierra Leone lifts ban on pregnant girls going to school but shutdown expected 
Hodal, K. | 31 March 2020 | The Guardian | News 
https://www.theguardian.com/global-development/2020/mar/31/sierra-leone-lifts-ban-on-
pregnant-girls-going-to-school-but-shutdown-expected 
Sierra Leone lifted its ban that prohibited pregnant schoolgirls from attending school and sitting 
exams last Monday, however, Sierra Leone is expected to close schools this week to prevent 
transmission of coronavirus. Sierra Leone is one of only eight virus-free countries in Africa. 
Lessons must be learnt from the Ebola outbreak where girls were left vulnerable to pregnancy and 
forced to fend for themselves after schools were closed for months on end, and which saw more 
than 18,000 girls fall pregnant. 
Estimates of the severity of coronavirus disease 2019: a model-based analysis 
Verity, R., Okell, L.C., Dorigatti, I., Winskill, P. Whittaker, C. et al. | Lancet Infectious Diseases | 
30 March 2020 | Article 
https://doi.org/10.1016/S1473-3099(20)30243-7 
From extensive analysis of data from different regions of the world, these early estimates of the 
case fatality ratio for COVID-19, although lower than some of the crude estimates to-date and 
lower than for SARS and MERS are substantially higher than for recent influenza pandemics (e.g. 
H1N1 influenza in 2009) and increase substantially with age. This study estimates an overall case 
fatality ratio in China of 1.38% (95% Crl 1.23-2.53). The average time to death from onset of 
symptoms was around 18 days. Estimates of the proportion of infected individuals likely to be 
hospitalised also increased with age and the average time to hospital discharge from onset of 
symptoms was around 25 days. The authors argue that crude case fatality ratios (dividing the 
number of deaths by the number of cases) can mislead because there can be a period of 2 to 3 
weeks between a person developing symptoms and that case being detected and reported, and 
because surveillance of a novel virus is biased towards detecting severe cases, especially at the 
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start of an outbreak when testing capacity is low. Although China has succeeded in containing the 
disease spread for 2 months, this is unlikely to be achievable in most countries and very large 
community epidemics of COVID-19 over the coming weeks and months will be experienced around 
the world. Estimates provided here can be applied to help inform forecasting of healthcare 
requirements and guide appropriate mitigation policies in different countries. 
Likelihood of survival of coronavirus disease 2019 
Ruan, S | The Lancet Infectious Diseases | 30 March 2020 | Comment  
https://doi.org/10.1016/S1473-3099(20)30257-7 
This Comment on Verity et al. (see above) discusses the challenges of estimating the case fatality 
ratio of COVID-19 in real time and how they may vary between countries because of differences 
in implementation of prevention, control and mitigation policies and is affected by the preparedness 
and availability of healthcare. Early studies have shown that delay in detection of infected cases 
increases probability of spread and can increase the case fatality ratio. Includes a comparison 
Figure of case fatality ratios for SARS, COVID-19 and seasonal influenza. Early detection early 
diagnosis, early isolation and early treatment are likely to be useful in controlling the outbreak and 
decreasing the case fatality ratio. 
An action plan to engage the private sector in the response to COVID 19 
Hanlon B. et al. | WHO | 30 March 2020 | Guidelines 
https://hsgovcollab.org/en/node/4365 
Draft interim guidance to help governments and their efforts to engage the private sector as part 
of a whole of society approach in responding to COVID-19 and to support governments to engage 
the private sector to help maintain essential health serves. 
Structural basis of receptor recognition by SARS-CoV-2 
Shang, J., Ye G., Shi, K. Wan Y. et al. | Nature | 30 March 2020 | Article 
https://doi.org/10.1038/s41586-020-2179-y 
This study provides initial suggestions that SARS-CoV-2 is more infectious than SARS-CoV, the 
coronavirus which caused the 2002 SARS epidemic, both of which bind the same receptor ACE-2 
where present on human cells but where SARS-CoV-2 is able to bind more efficiently. Thus when 
inhaled through the nose or mouth has a higher chance of attaching to cells here, where the levels 
of ACE-2 are thought to be lower, compared to SARS-CoV which almost always replicated in the 
lungs. This information will help research for potential anti-viral drugs that that can bind to the virus 
more strongly and more frequently than human ACE-2 to block viral entry into the cell and 
replication and will shape work on vaccine development. 
Developing Covid-19 vaccines at pandemic speed 
Lurie et al. from the Coalition for Epidemic Preparedness Innovation (CEPI) | NEJM | 30 March 
2020 | Perspective 
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https://doi.org/10.1056/NEJMp2005630 
Discusses the need to continue developing the most promising vaccine candidates beyond the 
end of a pandemic, should it abruptly end before vaccines are ready. An ideal vaccine platform 
would support development from viral sequencing to clinical trials in less than 16 weeks, induce 
consistent immune responses across pathogens, and be suitable for large scale manufacturing. 
Includes a summary Table of vaccine platforms, their attributes and the status of vaccine 
candidates and diagram comparing the difference between traditional vaccine development and 
development using a pandemic paradigm. 
Johnson & Johnson announces a lead vaccine candidate for COVID-19 
Johnson & Johnson | 30 March 2020 | News 
https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-
landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-
supply-one-billion-vaccines-worldwide-for-emergency-pandemic-us 
Johnson & Johnson have announced (1) a lead vaccine candidate for COVID-19 from constructs 
is has been working on since January 2020; (2) a landmark new partnership with the U.S. 
Department of Health & Human Services; and (3) a commitment to supply one billion vaccines 
globally for emergency pandemic use. The Company expects to initiate human clinical studies of 
it lead vaccine candidate at the latest by September 2020. 
Global humanitarian response plan COVID-19 
United Nation Coordinated Appeal | 25 March 2020 | Response plan 
https://www.unicef.org/press-releases/global-approach-only-way-fight-covid-19-un-says-it-
launches-humanitarian-response 
https://www.unocha.org/sites/unocha/files/Global-Humanitarian-Response-Plan-COVID-19.pdf 
The $2 billion global HRP COVID-19 will be coordinated by the UN’s Office for the Coorindation of 
Humanitarian Affairs and implemented by UN agencies, with international NGOs and NGO 
consortia and brings together requirements from WHO, FAO, IOM, UNDP, UNFPA, UNHCR, 
UNICEF, WFP. A warning is given to member states that any diversion of funding from existing 
humanitarian operations would create an environment in which other diseases - cholera, measles 
and meningitis – can thrive, more children become malnourished and in which extremists can take 
control – a “perfect breeding ground for the coronavirus”. 
Rights in the time of COVID-19: Lessons from HIV for an effective, community-led 
response 
UNAIDS | 20 March 2020 | Guidelines 
https://www.unaids.org/en/resources/documents/2020/human-rights-and-covid-19 
https://www.unaids.org/en/resources/infographics/human-rights-and-covid19_infographic 
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The new guidance (plus link above to the infographic) draws on key lessons from the response to 
the HIV epidemic to guide governments, communities and other stakeholders in planning and 
implementing measures to contain the COVID-19 pandemic. Seven takeaways: (1) communities 
are central; (2) no stigma and discrimination; (3) support the most vulnerable; (4) remove barriers 
to action; (5) no criminal sanctions; (6) international cooperation; and (7) be kind. 
Toward a disability inclusive COVID19 response: 10 recommendations from the 
International Disability Alliance 
IDA | 19 March 2020 | Recommendations 
http://www.internationaldisabilityalliance.org/sites/default/files/ida_recommendations_for_disabilit
y-inclusive_covid19_response_final.pdf 
Includes a list of the main barriers that persons with disabilities face in the COVID-19 emergency 
situation along with some practical solutions and recommendations. 
1. Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
An interactive web-based dashboard to track COVID-19 in real time 
https://www.nice.org.uk/covid-19 
Live data tracker: sex-disaggregated COVID-19 data from the 25 most-affected countries 
http://globalhealth5050.org/covid19 
Africa 
Coronavirus in Africa Tracker: How many covid-19 cases & where? 
https://africanarguments.org/2020/03/23/coronavirus-in-africa-tracker-how-many-cases-and-
where-latest/ 
UK 
COVID-19: PHE track coronavirus cases in the UK 
https://www.gov.uk/government/publications/covid-19-track-coronavirus-cases 
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UK case tracing infographic 
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4bb14 
2. Online course 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
A reminder that this course is currently running. On this course you will learn what is known 
about the outbreak of COVID-19 (week 1); what the practical implications for responding to 
COVID-19 are (week 2); and what we need to find out about COVID-19 (week 3). 
3. Resource Hubs 
International Disability Alliance: COVID 19 and the disability movement 
http://www.internationaldisabilityalliance.org/content/covid-19-and-disability-movement 
Africa Centres for Disease Control and Prevention (Africa CDC) 
https://africacdc.org/covid-19/ 
UNICEF: Latest news and updates on coronavirus disease 2019 (COVID-19) 
https://www.unicef.org/coronavirus/covid-19 
Coronavirus: the science explained 
https://coronavirusexplained.ukri.org/en/ 
Social Science in Humanitarian Action: Updates on the novel COVID-19 outbreak 
https://www.socialscienceinaction.org/update-novel-covid-19-outbreak/ 
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Special Collection: Coronavirus (COVID-19): evidence relevant to critical care 
https://www.cochrane.org/news/special-collection-coronavirus-covid-19-evidence-relevant-
critical-care 
NICE UK: Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
WHO: Coronavirus disease (COVID-19) outbreak resources 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.htmlThe Global Health Network Coronavirus 
outbreak knowledge hub 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
7 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campaign=
DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
Global Partnership for Sustainable Development – COVID-19 resources 
http://www.data4sdgs.org/resources/covid-19-resources 
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